Used in cancer immunotherapy to enhance immune cell activity against tumors by blocking the NKG2A receptor on natural killer (NK) cells and cytotoxic T cells. This inhibition prevents tumor cells from evading immune detection, particularly in cancers where HLA-E expression is upregulated. Monalizumab is being investigated in clinical trials for solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, and non-small cell lung cancer, often in combination with other checkpoint inhibitors like anti-PD-1/PD-L1 antibodies. It shows potential to improve response rates and prolong progression-free survival by boosting the body’s natural immune response to cancer.